(PRESS RELEASE) SAN DIEGO, CA — LENZ Therapeutics, Inc., announced VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, is now available. Professional product sample distribution by the sales force to optometrists and ophthalmologists has been initiated nationwide. Commercial product shipments will be initiated to consumers in October through our ePharmacy partner and is anticipated to be broadly available, including via retail pharmacies, by mid-Q4 2025.
Experience the full interactive Multichannel News Release here.
“We are thrilled to introduce VIZZ to the 128 million adults living with blurry near vision in the United States,” said Eef Schimmelpennink, President and Chief Executive Officer of LENZ Therapeutics. “The team has been preparing for this moment for months and worked tirelessly to enable the availability of product samples and commercial product following our FDA approval. Initial feedback and early brand awareness from the ECP community is extremely positive, and we feel well-positioned for a successful product launch, firmly establishing VIZZ as a Category of One for the treatment of presbyopia.”
VIZZ is powered by aceclidine, differentiated by its mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation. VIZZ contracts the iris sphincter muscle, resulting in a pinhole effect and uniquely achieves a sub-2mm pupil that extends depth of focus to significantly improve near vision without causing a myopic shift. In the CLARITY Phase 3 clinical trial, 93% of participants achieved 20/40 or better near vision within 30 minutes and lasted up to 10 hours. This level of near vision can restore the ability to read a phone screen and other everyday fine print without the assistance of reading glasses.
“With VIZZ now available, we’re giving people living with presbyopia a simple, fast-acting way to see up close again,” said Shawn Olsson, Chief Commercial Officer of LENZ Therapeutics. “It’s about restoring everyday confidence, including reading a phone, checking a price tag, or enjoying your active lifestyle glasses-free. We’re excited to bring this new option to millions who want more freedom in their near vision.”
For more information about VIZZ and full prescribing information, please visit www.VIZZ.com
Advertisement
Age-related vision loss (presbyopia) background infographic
VIZZ Indication and Important Safety Information
INDICATION
VIZZ (aceclidine ophthalmic solution) 1.44% is a prescription eye drop used to treat age-related blurry near vision (presbyopia) in adults.
IMPORTANT SAFETY INFORMATION
- Do not use VIZZ if allergic to any of the ingredients.
- To help avoid potential eye injury or contamination of the product, do not allow the vial tip to touch the eye or any surfaces. Discard the opened vial immediately after use.
- Contact lenses should be removed before using VIZZ. After dosing, contact lenses can be reinserted after 10 minutes.
- If using more than one topical eye medication, the medicines should be administered at least 5 minutes apart.
- Temporary dim or dark vision may be experienced after using VIZZ. Do not drive or operate machinery if vision is not clear.
- Seek immediate medical care if sudden onset of flashing lights, floaters, or vision loss is experienced.
ADVERSE REACTIONS
The most common reported adverse reactions of participants were instillation site irritation (20%), dim vision (16%), and headache (13%). Adverse reactions reported in >5% of participants were conjunctival hyperemia (8%) and ocular hyperemia (7%). The majority of adverse reactions were mild, transient, and self-resolving.
